News

Oculis Reveals Breakthrough Findings on Privosegtor Therapy

Oculis Reveals Breakthrough Findings on Privosegtor Therapy

Oculis Unveils Positive Phase 2 Trial Results for Privosegtor

Exciting news has emerged from Oculis Holding AG, a forward-thinking biopharmaceutical company specializing in treatments for ophthalmic and neuro-ophthalmic conditions. The company recently announced that it will present results from its Phase 2 ACUITY trial, which investigates Privosegtor (OCS-05) in treating acute optic neuritis, during the upcoming European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress.

Presentation Details at ECTRIMS 2025

At ECTRIMS, Oculis will highlight groundbreaking data demonstrating the efficacy of Privosegtor in a multicenter, randomized, placebo-controlled trial. The presentation, titled Reduction in Retinal Ganglion Cell Loss and Improved Low Contrast Visual Acuity with Privosegtor in Acute Optic Neuritis: Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial, is set for Wednesday, September 24, 2025, at 08:30 CET and will be delivered by Dr. Céline Louapre from Pitié-Salpêtrière Hospital.

Significance of the Findings

Dr. Riad Sherif, Chief Executive Officer of Oculis, expressed enthusiasm about the collaboration with Pitié-Salpêtrière Hospital. He shared, "Our Phase 2 ACUITY trial demonstrated clinically meaningful improvements in vision, with patients experiencing an average increase of 18 letters in vision over three months. The preservation of retinal structure and the favorable safety profile are very encouraging, suggesting that Privosegtor may have significant applicability in various neurological conditions.”

Dr. Louapre added her insights, stating, "Presenting at ECTRIMS is an honor, as it is one of the largest MS congresses worldwide. The results underline the possibility for Privosegtor (OCS-05) to have a transformative impact on patients suffering from acute relapses of multiple sclerosis, particularly since acute optic neuritis can frequently be the initial sign of this debilitating disease."

About Privosegtor (OCS-05)

Privosegtor is an innovative peptoid small molecule candidate focusing on neuroprotection for patients suffering from acute optic neuritis and other associated conditions. In the Phase 2 ACUITY trial, Privosegtor demonstrated not only anatomical preservation of retinal structures but also improvements in visual acuity. Animal studies mirrored these findings, with significant protection against retinal ganglion cell damage and enhancements in clinical functions.

This investigational drug has received orphan drug designations from both the FDA and EMA, highlighting its potential in treating acute optic neuritis. The implications for a neuroprotective treatment extend into numerous neuro-ophthalmic and neurological areas, underscoring the broad potential of this candidate.

Understanding Acute Optic Neuritis

Acute optic neuritis, a rare but serious condition, involves inflammation of the optic nerve that can lead to significant visual impairment. It predominantly affects individuals between the ages of 20 and 40 and occurs more often in women. Symptoms typically begin with ocular pain and subsequent vision loss which, if untreated, can lead to lasting damage due to the fragility of unprotected neurons.

About Oculis

Oculis is at the forefront of innovation in biopharmaceuticals, dedicated to addressing the growing needs in the fields of ophthalmology and neurology. With a pipeline that includes OCS-01, an eye drop aimed at diabetic macular edema; Privosegtor (OCS-05); and Licaminlimab (OCS-02), a topical treatment currently in Phase 2, the company exemplifies a commitment to pioneering research to enhance treatment options for patients. Headquartered in Switzerland, Oculis operates with a strong team experienced in delivering successful therapeutic solutions.

If you wish to know more about Oculis or its groundbreaking research, you can reach out through their corporate communications channels.

Frequently Asked Questions

What is the Phase 2 ACUITY trial?

The Phase 2 ACUITY trial investigates the efficacy of Privosegtor (OCS-05) in patients suffering from acute optic neuritis, focusing on visual function and retinal preservation.

Who presented the findings at ECTRIMS?

Dr. Céline Louapre from Pitié-Salpêtrière Hospital is set to present these findings at the ECTRIMS congress.

What were the main results of the trial?

The trial demonstrated a noteworthy improvement in vision with an average gain of 18 letters at the three-month mark, alongside enhanced retinal health.

What is the significance of Privosegtor?

Privosegtor is seen as a promising neuroprotective therapy, not only for acute optic neuritis but potentially for broader neurological applications.

What is Oculis' mission?

Oculis aims to innovate and provide solutions for ophthalmic and neuro-ophthalmic diseases, addressing significant unmet medical needs through their diverse product pipeline.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 130

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 104

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 55

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 45

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 76

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 115

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 108

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 67

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 50

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Freedom Jet Card Launched by FlyUSA for Travelers

Updated Category News Views 311

FlyUSA Launches the Freedom Jet Card for Enhanced Travel FlyUSA is taking the world of private aviation to new heights with the introduction of its groundbreaking Freedom Jet Card. This innovative service brings a fresh approach to private flying, offering travelers the assurance of predictable pricing combined with unmatched flexibility and a wide array of aircraft...

Continue Reading
Enovix Corporation's Recent Stock Offering: A Game Changer

Updated Category News Views 104

Enovix Corporation's Public Offering Overview Enovix Corporation, a leader in high-performance battery technology, has recently announced an underwritten public offering of 10,416,667 shares of its common stock. This initiative is expected to generate gross proceeds of around $100 million, paving the way for critical advancements in their production capabilities. The...

Continue Reading
HP, First Solar, Workday Facing Headwinds as Stocks Slide

Updated Category News Views 208

Markets in Motion: A Peek at Pre-Market Action The stock market's a fickle beast, isn’t it? The Dow futures are looking moderately optimistic, gaining about 0.1% this morning. But don’t let that sunshine fool you; beneath the surface, some big names are taking hits as investors reposition themselves. HP's Disappointing Movement HP Inc. just reported its quarterly...

Continue Reading
Outset Medical Faces Class Action Amid Earnings Shortfalls

Updated Category News Views 182

Outset Medical’s Legal Challenges and Market Response Outset Medical, Inc. (NASDAQ: OM) is currently facing class action litigation, which has raised concerns among its investors. The situation arose after the company disclosed significant operational challenges and regulatory issues that have impacted its stock performance significantly. Class Action Overview Pomerantz...

Continue Reading
Schneider Electric Showcases Sustainability at Climate Week

Updated Category News Views 80

Schneider Electric's Commitment to Sustainability at Climate Week NYC Schneider Electric is making significant strides in promoting sustainability during Climate Week NYC. The company is dedicated to a thorough approach to energy transition that fosters collaboration among various sectors. This effort isn't just about encouraging eco-friendly practices; it represents a...

Continue Reading